KLRK1 and ovarian carcinoma: VPA upregulates NKG2D ligands on ovarian cancer cells, enhancing their recognition by NKG2D CAR T-cells, which incorporate CD137 (4-1BB) costimulation for improved persistence and cytotoxicity.